Merck Inc., to acquire Imago BioSciences and with it IMG 7289 treatment for essential thrombocythemia, myelofibrosis and polycythemia vera.
Merck Inc., and Imago BioSciences, Inc. announced that the companies have entered into a definitive agreement under which Merck Inc., through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion
Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Imago’s lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, is currently being evaluated in multiple Phase II clinical trials for the treatment of essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV), in addition to other indications.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins